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ABSTRACT
The pharmacokinetics and pharmacodynamics of methadone
were investigated in control and abstinent rats. Minipumps
filled with saline (control group) or saline-morphine (abstinent
group) solutions were used to induce physical dependence.
Solutions were delivered continuously by minipumps for 6
days. The physical dependence was evaluated 12 h after
minipump removal by measuring specific withdrawal signs.
Animals from the abstinent group showed clear withdrawal
signs such as hostility on handling and weight loss. Plasma and
brain disposition and pharmacodynamics of methadone were
evaluated after a 0.35 mg/kg i.v. bolus dose administered 12 h
after minipump removal. Plasma clearance, distribution clear-
ance, and volume of distribution at steady-state were signifi-
cantly decreased (P , 0.05) in the abstinent group. Plasma
levels of a1-acid glycoprotein and plasma protein binding were
significantly increased (P , 0.05) in the abstinent group. The
estimates of pharmacokinetic parameters based on unbound
plasma concentrations did not differ between groups, with the
sole exception of the unbound apparent volume of distribution.
The access of methadone to the brain was significantly faster
(P , 0.05) in the abstinent group, although the extent of distri-
bution in the brain was diminished in comparison with the
control group. Analgesia recorded with tail-flick was used as
the pharmacodynamic endpoint. Analgesic response and effect
compartment concentrations of methadone were related by the
sigmoidal Emax model. Estimates of C50 [steady-state plasma
concentrations eliciting half of maximum effect (Emax)]] based
on unbound concentrations did not differ between groups. On
the other hand, the estimate of Emax had decreased by 65% in
the abstinent group.
The study of the pharmacokinetic-pharmacodynamic
(pk/pd) relationships of opioid drugs can be hampered by
various factors such as 1) the development of acute and/or
chronic tolerance (Ekblom et al., 1993; Ga˚rdmark et al.,
1993), 2) disease (Inturrisi et al., 1987), 3) withdrawal
syndrome (developed after stopping continuous exposure
to an opioid; Adams and Holtzman, 1990), and 4) cross-
tolerance phenomena (Paronis and Holtzman, 1992).
Among all these, only the development of tolerance has
been studied to some extent under the pk/pd perspective;
recently, models have been proposed to account for the
development of tolerance for morphine (Ekblom et al.,
1993; Gårdmark et al., 1993; Oullet and Pollack, 1995) and
alfentanil (Mandema and Wada, 1995) in healthy (control)
rats following different modes of drug administration. Less
attention has been paid to the effect of disease on the pk/pd
properties of this kind of drug, although Inturrisi et al.
(1987) explore by means of a pk/pd model the analgesic
effects of methadone in cancer patients.
Regarding withdrawal syndrome, it is well known that
this status can produce physiological alterations such as
weight loss (Goode, 1971), changes in plasma protein level
(Garrido et al., 1996), diarrhea (Goode, 1971) etc., all of
which may modify drug kinetics. To our knowledge, the
disposition of opioids has not been characterized with re-
gard to such a syndrome; there are studies in which the
plasma and brain levels of the opioid methadone were
compared between abstinent and healthy rats (Liu et al.,
1983), but no pharmacokinetic models were proposed.
In addition, drug efficacy and/or drug potency are likely
to be altered during withdrawal because there has been a
previous exposure to an opioid (Paronis and Holtzman,
1992); for example, the drug potency, evaluated as ED50,
was increased for fentanyl and etorphine, after a previous
3-day exposure to morphine pellets (Brase, 1986). Al-
though the response to opioids in opioid-treated rats has
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been extensively studied, most of those studies were based
on dose-response relationships (Craft and Dykstra, 1990;
Paronis and Holtzman, 1992), and, consequently, no data
are available about the contribution of pharmacokinetic
and pharmacodynamic (response versus drug concentra-
tion relationship) changes to the response versus time
profile and/or in the dose-response relationships. The cur-
rent study was design to characterize the disposition and
response of an opioid in healthy and morphine treated rats
that developed opioid dependence; such dependence was
assessed by evaluating specific withdrawal signs. Metha-
done was used because it is the drug of choice in the
treatment of withdrawal signs (Wolff et al., 1991) and
because its pk/pd properties have been studied less than
morphine (Gårdmark et al., 1993), alfentanil (Mandema
and Wada, 1995), or buprenorphine (Ohtani et al., 1994).
Methadone was administered by i.v. bolus to minimize the
development of tolerance. The possible changes in the ki-
netic and dynamic processes were evaluated by the com-
parison of pharmacokinetic and pharmacodynamic param-
eters between healthy and abstinent rats. We used
methadone plasma concentrations (total and unbound) as
a measure of drug exposure, and the analgesic response
recorded with tail-flick as the pharmacodynamic endpoint.
The disposition of methadone in the brain was also evalu-
ated.
Materials and Methods
This manuscript reports both in vivo and in vitro studies. Three in
vivo experiments were performed: plasma (experiment I) and brain
(experiment II) disposition of methadone and analgesic effect of
methadone (experiment III). During the in vitro study, the plasma
protein binding of methadone and the levels of a1-acid glycoprotein
(AAG) in plasma were determined. In each of these experiments,
control and abstinent (showing withdrawal signs) rats were used. All
experiments were carried out between 8:00 AM and 12:00 AM to
minimize circadian variations.
In Vivo Studies
Animals and Surgical Procedure. Male Sprague-Dawley rats
(220–280 g) obtained from Criffa (Barcelona, Spain) were kept at a
controlled temperature of 20°C and a humidity of 70% with a normal
12-h light/dark cycle (8:00 AM to 8:00 PM) for 4 days before the
experiment was performed. The animals had free access to food and
water. The protocol of the study was approved by the Committee on
Animal Experimentation of University of the Basque Country.
Two minipumps (Alzet mod 2001, Palo Alto, CA) filled with saline
(control group) or morphine solution (abstinent group) were im-
planted at 1cm under the skin of each animal. Under light ether
anesthesia, the implant was inserted behind the neck next to the
dorsal area; this area was shaved and swabbed with povidone iodide.
The minipumps were removed under light ether anesthesia 6 days
later and at the same time, a polyethylene catheter [inside diameter
(I.D.) 0.5 mm and 10 cm long, Vygon, France] was implanted in the
right jugular vein for the i.v. administration of methadone. In the
animals from experiment I, the carotide artery was cannulated with
a polyethylene catheter (I.D. 0.5 mm and 10 cm long, Vygon) for
blood sample collection. All catheters were filled with a physiological
saline solution containing 1% of heparin (50 I.U./ml; Roger Lab,
Spain) to prevent clotting. The catheters were tunneled under the
skin and externalized on the dorsal surface of the neck.
Induction of Physical Dependence on Morphine. Minipumps
filled with saline morphine solution were used to induce physical
dependence in treated animals. Morphine was delivered continu-
ously at a rate of 0.5 ml/h for 6 days (Adams and Holtzman, 1990); the
daily dose was 10 mg/kg.
Morphine Withdrawal and Abstinence Syndrome Measure-
ment. The severity of spontaneous-abstinence syndrome was evalu-
ated in control and morphine-treated rats just before (0 h) and 12 h
after minipump removal. Each animal was placed in an acrylglass
box and was observed for a period of 10 min. The following signs were
measured: hostility on handling, diarrhea, and body weight loss.
These signs are considered the most representative in the evaluation
of abstinence syndrome (Bla¨sig et al., 1973). Diarrhea and hostility
on handling were recorded as 0 (absent) or 1 (present). Body weight
loss was evaluated as the difference between the weights recorded
just before and 12 h after minipump removal.
Morphine Assay. In each animal, plasma levels of morphine
were measured by RIA kit Coat-a-Count serum morphine (Dipesa,
Spain) at 0 and 12 h after the minipumps were removed. A volume of
100 ml of blood was withdrawn through the catheter placed in the
jugular vein. The blood was centrifuged at 2500 rpm for 15 min and
25 ml of plasma were used for morphine determination. This proce-
dure was sensitive to 0.8 ng/ml and the antiserum had only 0.2%
cross reactivity with morphine glucuronides (Bhargava et al., 1992).
Experiment I: Disposition of Methadone in Plasma. Twelve
hours after the minipumps were removed, the control (n 5 41) and
abstinent (n 5 33) animals, received a 0.35 mg/kg i.v. bolus dose of
methadone in 30 s. The drug was administered in a saline solution.
This dose of methadone was found to elicit analgesia with minor
adverse respiratory effects (Go´mez et al., 1995). Blood samples (one
for each animal) were obtained at 1, 2, 3, 4, 5, 7.5, 10, 15, 30, 60, 90,
and 120 min after drug administration; 3 to 4 animals were used at
each time point. Arterial blood samples (2 ml) were centrifuged at
2500 rpm for 15 min. The plasma was immediately analyzed by
high-performance liquid chromatography following the method of
Wolff et al. (1991) with some modifications. Methadone and ben-
zhexol (used as internal standard) were determined by UV detection
using a wavelength of 250 nm. Afterward 0.5 ml of 1 M sodium
carbonate buffer solution (adjusted to pH 5 10 with sodium hydro-
gen carbonate solution 1 M) and 5 ml of a saturated water solution of
n-butyl chloride were added to 1 ml of plasma in glass tubes. The
mixture was mechanically shaken for 15 min and then centrifuged at
4°C for 10 min at 4000 rpm. The n-butyl chloride upper layer was
placed in a 5-ml glass tube and then evaporated at 50°C (AES 1000,
Speed Vac concentrator; Savant, Spain). The residue was dissolved
in 0.1 ml of methanol, and a volume of 50 ml was injected into the
chromatographic system. The liquid chromatographic system con-
sisted of a pump (HPLC pump 422; Kontron Instruments, Bilbao,
Spain), a UV detector (Waters 480), and an integrator (Y-549, Kon-
tron Instruments, Bilbao, Spain). Chromatography was performed
on a silica 5-mm column, Apex I 25- 3 0.46-cm I.D. (Teknocroma,
Barcelona) at 20°C. The mobile phase consisted of a mixture of
methanol:1,2-dichloroethano:isopropanol 100 g/liter ammonium per-
chlorate aqueous solution (90.5:5:4:0.5 v/v) at a flow rate of 2 ml/min.
This analytical procedure is sensitive to 5 ng/ml for methadone and
linear over the range 5 to 250 ng/ml; the mean intra- and interassay
precision and extraction efficiencies were 91.0% (5.6), 92.4% (3.2), and
87.1% (4.7) [mean (S.D.); n 5 3], respectively.
Experiment II: Disposition of Methadone in Brain. Twelve
hours after the minipumps were removed, the animals, control (n 5
38) and abstinent (n 5 37), received a 0.35 mg/kg i.v. bolus dose of
radiolabeled methadone. The drug was administered in 30 sec. The
animals were sacrificed by decapitation at 1, 2, 3, 4, 5, 7.5, 10, 15, 30,
60, 90, and 120 min after drug administration; 3 to 4 animals were
used at each time point. The brains were rapidly removed and 100
mg of brain (cortex) was dissected (Dhawan et al., 1996). Tissue
samples (100 mg) were mixed with 1 ml of tissue solvent (Scharlau,
Barcelona, Spain) and were incubated for 48 h at 37°C; 10 ml of
scintillation solution (NEF 989, DuPont, Barcelona, Spain) was
added and the mixture was placed at room temperature for 2 h. The
[14C]methadone concentrations were measured by scintillation
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counting using a Packard model 300-Tri-Carb Spectrometer (Go´mez
et al., 1995).
Experiment III: Analgesic Assay. The pharmacodynamics of
methadone was studied in the control group (n 5 18) and abstinent
group (n 5 15). The radiant-heat tail-flick technique was used to
assess the nociceptive threshold (D’Amour and Smith, 1941). Tail-
flick latency was measured automatically with a Letica (Barcelona,
Spain) analgesimeter. The intensity of heat was adjusted so that
control latencies were 2 to 3 s; animals with longer baseline latencies
were excluded. A maximal cut-off time of 10 s was used to prevent
tissue damage. The animals were tested for analgesia at 12 h after
minipump removal (this value was taken as the baseline level for
each animal) and at the following times after methadone adminis-
tration: 1, 2, 3, 4, 5, 10, 15, 30, 45, 60, 90, and 120 min (control) and
1, 5, 7.5, 10, 15, 30, 45, 60, 90, and 120 min (abstinent). Antinoci-
ception was expressed as a percentage of maximum possible re-
sponse (%MPR) and was calculated using the following expression:
%MPR 5 (test latency – baseline latency) * 100/(cut-off time –
baseline latency)
In Vitro Studies
Animals and Surgical Procedure. Male Sprague-Dawley rats
(220–280 g) obtained from Criffa (Barcelona, Spain) were kept in the
same conditions as the animals used for in vivo studies. For the in
vitro studies, two groups were also used, a control group ( n 5 10)
and abstinent group (n 5 10). To induce physical dependence on
morphine, two minipumps filled with morphine solution or saline,
were implanted in these animals. The surgical procedure was the
same as described in the in vivo studies. No catheters were im-
planted in these groups of animals. The spontaneous abstinence
syndrome was also assessed as was described above for the in vivo
experiments. All animals were sacrificed by decapitation 12 h after
minipump removal, and the blood was collected and immediately
centrifuged for 15 min at 2500 rpm. Plasma samples (3 ml) were
stored at –20°C for quantification of [14C]methadone plasma protein
binding, AAG, and morphine levels.
14C-Methadone Plasma Protein Binding and Mucoprotein
Assay. The protein binding was determined at 37°C by ultrafiltra-
tion, using a micropartition system (Amicon MPS-1) (March and
Blanke, 1985). An aqueous solution (10 ml) of [14C]methadone was
added to 990 ml of plasma to a final drug concentration of 70 ng/ml
(analgesic concentration in rats; Go´mez et al., 1995). These samples
were centrifuged at 3000 rpm for 5 min, and a volume of 100 ml was
collected to measure the unbound methadone concentrations by scin-
tillation spectrometry (Packard model 300-Tri-Carb Spectrometer).
For mucoprotein assay, 0.5 ml of plasma were used to evaluate AAG
levels, measured as mucoproteins, following Thaw and Albutt’s
method (Thaw and Albutt, 1980).
Data Analysis
Pharmacokinetic Analysis. The total concentration of metha-
done (C) and unbound plasma concentration of methadone (Cu) ver-
sus time profiles were described by a two-compartmental model. Cu
in control and abstinent rats was obtained by multiplying C by the
corresponding mean value of the unbound fraction in plasma (fu)
obtained from the in vitro studies. The total brain concentration of
methadone (Cbrain) versus time profiles were described by the follow-
ing model:
dCbrain/dt 5 k13 3 C 2 k31 3 Cbrain
where dCbrain/dt represents the rate of change of Cbrain, k13, and k31
are first-order rate constants governing the distribution processes of
methadone between plasma and brain; for such analyses, the pre-
dicted C versus time profiles obtained from the previous pharmaco-
kinetic analysis were used.
Estimation of Effect-Site Concentrations for Pharmacody-
namic Modeling. Because a counterclockwise hysteresis was noted
for both control and abstinent rats, when mean response data were
plotted against predicted C in a time-ordered manner, a model link-
ing the plasma compartment with the effect site by a first-order
process, the exit rate for which is denoted by ke0, was used; ke0 was
estimated nonparametrically (Verotta and Sheiner, 1987). Once ke0
has been obtained, the effect-site concentrations are generated and
can be used in the pharmacodynamic analyses.
Pharmacodynamic Analysis. The mean response versus pre-
dicted effect-site concentration relationships were described using
the Sigmoidal Emax model.
All of the analyses were performed using the “naive-pool data”
approach, in which all the data were fitted together as if they had
come from a single individual. In attempting to propose a model with
the maximum number of parameters in common between the control
and abstinent rats, the data from the two groups were fitted simul-
taneously. In the first stage, a reduced model was fitted to the data;
in this model, the two groups share all the parameters. In the
following stage, the models fitted to the data have some parameters
in common for the two groups, but not all; the last model fitted is the
full model, which has a complete different set of parameters for each
group. All the analyses were performed using the NONMEM (Beal
and Sheiner, 1992) computer program. The model selection was
based on a number of criteria, including 1) the visual inspection of
the residual plots, 2) the confidence intervals of the parameter esti-
mates, and 3) the value of the objective function given by NONMEM.
The difference between the objective function values for two hierar-
chical models is approximately x-square distributed and may be used
for model selection (Boeckmann et al., 1992). In this study P , 0.05
was used as the level of significance.
Statistical Analysis. Comparisons between fu and AAG levels
from the two groups were made by the unpaired t test. Comparisons
between weights and plasma levels of morphine just before and 12 h
after minipump removal were made by the paired t test, while the
differences in the hostility on handling and diarrhea between 0 and
12 h after minipump removal were evaluated by the paired McNe-
mar test.
Drugs. Morphine clorhydrate and methadone clorhydrate were
supplied by Alcaliber (Madrid, Spain). [14C]methadone (specific ac-
tivity 30 mCi/mmol and 98.8% of purity) was supplied by Amersham
(Barcelona, Spain). Benzhexol clorhydrate was obtained from Led-
erle Lab. (Madrid, Spain). All reagents and solvents used were of
analytical grade.
Results
Withdrawal and Morphine Measurements. Figure 1
shows the percentage of animals from the abstinent group
displaying hostility on handling, diarrhea (top), and body
weight loss (bottom) at 0 and 12 h after minipump removal.
The percentage of animals showing hostility on handling and
diarrhea after 12 h was statistically increased (P , .0001)
with respect to the number of animals showing the same
signs at 0 h; in addition, a significant decrease (P , .0001) in
body weight was found between 0 h (286 6 11 g) and 12 h
after minipump removal (267 6 10 g). Plasma levels of mor-
phine at 12 h (14 6 3 ng/ml) were found to be significantly
decreased (P , .0001) with respect to those obtained at 0 h
(111 6 9 ng/ml). No significant differences in any of the
withdrawal signs between 0 and 12 h after minipump re-
moval were found in the control group.
Plasma Disposition of Methadone. C and Cu levels of
methadone versus time profiles were best described, in both
control and abstinent groups, by a two-compartmental
model. Figures 2 and 3 show the experimental versus time
data with the pharmacokinetic model predictions superim-
posed for C and Cu, respectively. Table 1 lists the estimates
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of the pharmacokinetic parameters and their coefficients of
variation obtained during the analysis of the C versus time
profiles. Both groups showed similar initial volume of distri-
bution (V1) and mean residence time (MRT) values; however,
in abstinent rats, volume of distribution at steady state (Vss),
distribution clearance (Cld), and total plasma clearance (Cl)
were 42%, 23%, and 40% decreased, respectively, in respect
to the control group (P , .05). The in vitro binding of meth-
adone to plasma proteins and the AAG levels were signifi-
cantly increased (P , .05) in the abstinent group: fu, 0.172 6
0.1, abstinent, 0.254 6 0.11, control; AAG, 1.30 6 0.12 g/liter,
abstinent, 0.36 6 0.16 g/liter, control. Table 2 lists the esti-
mates of the pharmacokinetic parameters and their coeffi-
cients of variation obtained during the analysis of the Cu
versus time profiles. Both groups showed similar plasma
unbound concentrations kinetics (see Fig. 3); estimates of
unbound initial volume of distribution (V1u), unbound distri-
bution clearance (Cldu), and unbound plasma clearance (Clu)
did not differ between the two groups; only unbound volume
of distribution at steady state (Vssu), and unbound mean
residence time (MRTu) were 18% and 27% decreased, respec-
tively, in abstinent rats with respect to the control group (P ,
.05).
Brain Disposition of Methadone Fig. 4 shows the Cbrain
versus time data for both control and abstinent rats and the
predicted values obtained from the fit according to the model
described in the methods section. Estimates of brain dispo-
sition parameters, and their coefficients of variation were the
following: k135 2.1(15), control; 3.2 (20) min
21, abstinent
(P , .05); k315 0.30 (7), control; 1 (10) min
21, abstinent (P ,
.05). The plasma to brain distribution clearance (Cldb) and
the apparent volume of the brain compartment (VT) were
determined using the following expression:
Cldb 5 k13 3 V1 5 k31 3 VT
Using the estimates of V1 listed in Table 1, Cldb was esti-
mated to be 2.50, control, and 4.05 liters/min/kg, abstinent;
VT was estimated in 8.3, control and 4.05 liters/kg abstinent.
Based on model predictions, the maximums were achieved at
10 min after drug administration in the control group and
almost immediately after drug injection in the abstinent
group.
Pharmacodynamics of Methadone. Figure 5 shows the
time course of the mean analgesic effect in both groups.
Analgesia was significantly (P , .05) higher in control ani-
mals at times 1, 5, 10, and 15 min after drug injection.
Baseline analgesic values did not differ between the two
groups. In both groups the mean maximum of analgesia
appears at approximately 10 min after methadone adminis-
tration. When the analgesic effect versus C data were plotted
in a time-ordered manner, counterclockwise hysteresis was
noted; the greatest effect was seen after the peak plasma
concentrations. Table 3 lists the pharmacodynamic parame-
ters and their coefficients of variations. Emax (maximum at-
tainable effect) was 65% decreased (P , .05), and C50 (steady-
state plasma concentration of methadone eliciting 50% of
Emax) was 38% increased (P , .05) in the abstinent group in
respect to the control group; ke0 (rate constant of equilibrium
between the effect and plasma compartments), was 28% in-
creased in the abstinent rats. The half-life of equilibration
between plasma and effect-site compartment was 0.67 min
and 0.48 min, for abstinent and control group, respectively.
Figure 6 shows the analgesic effect versus estimated effect-
site concentration relationships for both groups. This rela-
tionship was best described in both groups by a sigmoidal
Emax model. When C50 estimates were corrected by the dif-
ferences in the plasma protein binding found between two
groups, the unbound C50 values were 6.14, control, and 5.78
ng/ml, abstinent. Figure 7 shows the time course of the mean
observed and the model predicted (based on total plasma
concentrations) analgesic effects.
Discussion
In this article, we have explored the changes in the plasma
and brain disposition kinetics in addition to the changes in
the pharmacodynamic relationships of methadone occurring
during withdrawal from morphine in the rat.
The method used in the current study to induce opioid
Fig. 1. Percentage of animals from abstinent group displaying hostility
on handling and diarrhea at 0 h and 12 h after minipump removal (top);
and the body weight loss of animals from abstinent group at 0 h and 12 h
after minipump removal (bottom). *** (P , .0001), * (P , .05) statistically
different from 0 h.
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dependence has been previously used by other investigators
(Adams and Holtzman, 1990). This method, which involves
the continuous exposure to morphine for 6 days, has been
found suitable for producing physical dependence and cross-
tolerance. The degree of physical dependence was assessed
by emergence of a spontaneous withdrawal syndrome after
removal of the maintenance drug. Many investigators have
characterized this phenomenon by measuring some behav-
ioral or/and physiological changes, such as weight loss, diar-
rhea, and hostility on handling (Pierce et al., 1996). On the
basis of the results obtained for those signs (Fig. 1), it can be
concluded that the rats receiving morphine continuously for
6 days presented a clear abstinence syndrome 12 h after
minipump removal.
Our results obtained from the in vitro experiments showed
a significant increase in the levels of AAG in the abstinent
group. That increase was similar to the one reported by
Fig. 2. Total plasma concentrations of methadone
versus time profiles after a 0.35 mg/kg i.v. bolus
dose. Symbols represent experimental observa-
tions: open circles (control), diamonds (abstinent).
Lines represent model predictions: solid (control),
dashed (abstinent).
Fig. 3. Unbound plasma concentrations of meth-
adone versus time profiles after a 0.35 mg/kg i.v.
bolus dose. Symbols represent experimental ob-
servations: open circles (control), diamonds (absti-
nent). Lines represent model predictions: solid
(control), dashed (abstinent).
TABLE 1
Unbound fraction in plasma [mean (CV(%)] and pharmacokinetic
parameters based on total concentrations of methadone in plasma
expressed as estimate [CV(%)] in control and abstinent rats after a
0.35 mg/kg i.v. bolus dose
Parameter Control Abstinent
fu 0.254 (45) 0.172 (61)*
Vl (l/kg) 1.24 (34) 1.35 (34)
Vss (l/kg) 6.55 (9) 3.82 (6)*
Cld (l/min/kg) 1.45 (10) 1.12 (22)*
Cl (l/min/kg) 0.10 (17) 0.06 (10)*
MRT (min) 64.7 (45) 62.9 (12)
* Different from control group (P , 0.05).
TABLE 2
Pharmacokinetic parameters based on unbound concentrations of
methadone in plasma expressed as estimate [CV(%)] in control and
abstinent rats after a 0.35 mg/kg i.v. bolus dose
Parameter Control Abstinent
Vlu (l/kg) 7.75 (34) 8.42 (34)
Vssu (l/kg) 27.3 (9) 22.5 (6)*
Cldu (l/min/kg) 5.10 (10) 5.54 (22)
Clu (l/min/kg) 0.34 (17) 0.36 (10)
MRTu (min) 80.3 (417) 60.9 (16)*
* Different from control group (P , 0.05).
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Garrido et al. (1996) 12 h after morphine withdrawal in the
rat. There are many physiopathogical alterations in which
the AAG levels are significantly increased (burns, surgery,
inflammatory diseases; Go´mez et al., 1995); in general all
those conditions are stress related. Withdrawal signs, such
as weight loss, hostility on handling, and diarrhea, can be
considered reactions to a high-stress situation, leading there-
fore to an increase in the AAG levels. Similar results were
obtained in a study comparing the AAG levels between
healthy volunteers and opioid addict subjects (unpublished
results).
Methadone binds predominantly in plasma to AAG to a
high degree, 86 to 89%, in humans (Inturrisi et al., 1987) and
80% in the rat (Go´mez et al., 1995). These protein binding
characteristics could explain the decrease in fu in plasma
found in the abstinent group with respect to control rats.
There is also the possibility of a protein binding interaction
between methadone and morphine and/or metabolites of
morphine; but given the low protein binding characteristics
of morphine and metabolites (Vozeh et al., 1989), such inter-
action is unlikely to occur. In addition, the value of fu ob-
tained for the abstinent group is in agreement with the value
of fu in plasma reported from animals suffering an induced
experimental inflammation with a similar increase in the
AAG levels to that observed in the current study (Go´mez et
al., 1995).
The estimates of the parameters obtained in the current
study are in accordance with those published previously by
Ling et al. (1981) in control rats and by Gabrielsson et al.
(1985) in a study carried out in pregnant rats. However,
significant changes between the abstinent and control rats
were found in the plasma disposition of total concentrations
Fig. 4. Brain concentrations of methadone versus
time profiles after a 0.35 mg/kg i.v. bolus dose.
Symbols represent experimental observations:
open circles (control), diamonds (abstinent). Lines
represent model predictions: solid (control),
dashed (abstinent).
Fig. 5. Time course of the analgesic effects of
methadone after a 0.35 mg/kg i.v. bolus dose. Sym-
bols represent mean experimental observations:
open circles (control), diamonds (abstinent). Lines
represent linear interpolation: solid (control),
dashed (abstinent). Vertical lines represent stan-
dard deviations: * statistically different from ab-
stinent group (P , .05).
TABLE 3
Pharmacodynamic parameters expressed as estimate [CV(%)] in control
and abstinent rats after a 0.35 mg/kg i.v. bolus dose
Parameter Control Abstinent
Emax (%) 85.8 (6.2) 38.7 (14)*
C50 (ng/ml) 24.2 (6.6) 33.6 (14)*
g 4.8 (25) 4.8 (25)
* Different from control group (P , 0.05).
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of methadone. The changes were found in both the distribu-
tion and elimination processes. Given the parameter values
obtained for the control group, methadone is an extensively
distributed drug with a high plasma clearance, which a priori
allows us to predict a proportional change in the apparent
volume of distribution with a change in fu in plasma (Row-
land and Tozer, 1995a). Such a prediction seems to be con-
firmed by the results in Table 1. On the contrary, changes in
fu should not affect the total plasma clearance (Rowland and
Tozer, 1995b). The decrease in the total plasma clearance
found in the abstinent group is a result that is difficult to
explain. We have no evidence of an eventual decrease in
hepatic activity during withdrawal, and therefore we ex-
pected minor modifications in the clearance of methadone.
Several hypotheses can be formulated, such as hepatic inhi-
bition caused by continuous and previous exposure to mor-
phine. Another possibility is related to the fact that the
elimination of drugs can be affected by plasma proteins be-
yond simply regulating the fu in plasma.
Results from several studies have suggested a decrease in
the intrinsic clearance of drugs in situations in which the
AAG levels were increased (Quin et al., 1994). The estimates
of the pharmacokinetic parameters based on unbound
plasma concentrations showed that most of the changes
found in the plasma disposition of total concentrations of
methadone in the abstinent group could be explained by the
decrease in fu (see Fig. 3).
We measured [14C]methadone in the brain because in pre-
vious studies it has been demonstrated that more than 90%
of [14C]methadone in brain was unchanged (Liu et al., 1983).
Disposition of methadone in the brain differs also between
control and abstinent rats. Distribution of methadone in the
brain in the abstinent group is faster (Fig. 4). This phenom-
enon could be explained by taking into account the fact that
for highly lipophylic drugs, such as methadone, the rate of
tissue distribution is a nonrestrictive process that depends
on the total drug plasma concentrations rather that on the
unbound plasma concentrations (Rowland and Tozer, 1995a).
So, the higher total plasma concentrations found in the ab-
stinent group produced a faster entry into the brain, as has
Fig. 6. Analgesic effect versus the effect-site con-
centration (Ce) relationship of methadone. Ce es-
timated based on total methadone plasma concen-
trations. Symbols represent mean experimental
observations: open circles (control), diamonds (ab-
stinent). Lines represent model predictions: solid
(control), dashed (abstinent).
Fig. 7. Time course of the analgesic effects of
methadone after a 0.35 mg/kg i.v. dose. Symbols
represent mean experimental observations: open
circles (control), diamonds (abstinent). Lines rep-
resent model predictions obtained from the phar-
macokinetic/pharmacodynamic model selected:
solid (control), dashed (abstinent).
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been reflected in the estimates of k13. Similar results have
been reported for other lipophylic drugs highly bound to
AAG, such as lidocaine (Marathe et al., 1991), in situations in
which the AAG levels were significantly increased. Several
studies have explored the brain disposition of methadone in
rats (Liu et al., 1983; Gabrielsson et al., 1985) but none
compared control with withdrawal condition. Our results
obtained from the control group are similar to those reported
by Gabrielsson et al. (1985), where the partition coefficient
between brain and plasma was estimated as 4.57, a value
similar to the one estimated in the present study using the
Chen and Gross approach (Chen and Gross, 1979).
Figure 5 shows a significant decrease in the analgesic
effect versus time profile for the abstinent group with respect
to the control group. One might think, on the basis of our
results regarding the decrease in the extension of drug dis-
tribution, that the observed minor effect could be caused by
kinetic modifications. To analyze eventual alterations in the
dynamic processes, pharmacodynamic modeling of the data
is required. Because in the current study we measured total
plasma and brain methadone concentrations, we needed to
choose the most adequate drug exposure measurement be-
fore data modeling was possible. We decided to use the total
plasma concentrations for three reasons: 1) brain concentra-
tions are rarely measured, although, methadone plasma con-
centrations have been measured in patients in several stud-
ies (Inturrisi et al., 1987); 2) as can be observed from Figs. 4
and 5, the brain methadone concentrations versus time pro-
file in the case of control group appears to be in equilibrium
with the analgesic effect versus time profile, however, a coun-
terclockwise hysteresis was noted for the abstinent group;
and 3) there are alternatives, like the effect compartment
model (Sheiner et al., 1979), that allows for pharmacody-
namic parameter estimations in cases of temporal displace-
ments between plasma drug concentration and response.
The value of keo obtained for the abstinent rats was esti-
mated as being lower than the one obtained for the control
rats. For the morphine-treated group, taking into account the
fact that entry into the brain is almost instantaneous after
drug injection, the value of keo would represent delays in
signal transduction; but for the control group, keo could re-
flect the delay in entering into the brain. To analyze the
dynamic properties of methadone, we simply related the
mean observed responses with the estimates of the metha-
done effect-site concentrations using a sigmoidal Emax model.
Tolerance development has been described after bolus injec-
tion of morphine (Kissin et al., 1991); if such acute tolerance
development had occurred in the current study, a clockwise
hysteresis would be noted in the effect versus plasma con-
centration plot. No such phenomenon was observed, and we
concluded that either no or minor acute tolerance for meth-
adone was developed. There is a possibility of a pharmaco-
dynamic drug interaction between methadone and morphine
and/or metabolites of morphine in the abstinent group, but
we think that such interaction is unlikely because the mea-
sured morphine plasma concentrations are very low in com-
parison with the values of C50 for morphine estimated by
other authors [approximately 400 ng/ml by Ouellet and Pol-
lack (1997)] and also because the baseline analgesic values
obtained were not significantly different from those obtained
for the control group.
Another important issue in the pharmacodynamic analysis
is the presence of active metabolites that can hamper the
interpretation of results. The data in the literature suggest
that the main metabolites of methadone are pharmacologi-
cally inactive (Liu et al., 1983). Methadone is commonly
administered as a racemic mixture of the l- and d-isomers,
the l-isomer being responsible for the opioid pharmacological
activity and the d-isomer inactive. Recently, Kristiensen et
al. (1996) reported the pharmacokinetic parameter estimates
for both isomers in humans. The estimates for clearance were
156 and 130 ml/h for the l- and d- isomers, respectively. The
values of the apparent volume of distribution at steady state
were 490 (l-isomer) and 290 (d-isomer) liters. Both isomers
showed a similar high value for plasma protein binding (ap-
proximately 90%). These data allow us to assume a parallel
shift in the kinetics of both isomers during withdrawal with
respect to the kinetics in a control condition. On the basis of
the above, the use of a simple model to relate response with
effect site drug concentrations seems to be appropriate.
The estimate of drug potency (C50) was 24.2 ng/ml. That
estimate, when corrected by fu in plasma, was 6 ng/ml (1.6
nM), a value close to the one reported by Magnan et al. (1982)
for the affinity of methadone for the m-opioid receptors (KI 5
4.5 nM). Once C50 for both groups was corrected by the
changes in fu, drug efficacy reflected by the estimate of Emax
was the only pharmacodynamic parameter differing between
the two groups. There is no clear consensus about what type
of alteration in the m-receptor system is involved by previous
exposure to opioids or/and during an abstinence syndrome.
Several investigators have reported changes at the receptor
level, in terms of down-regulation (Dı´az et al., 1995) after
continuous exposure to an opioid, but also an up-regulation of
the opioid system between 6 to 72 h after a spontaneous
abstinence syndrome of morphine, (Ullibarri et al., 1987;
Bhargava and Gulati, 1990). We cannot think of a mecha-
nism that could explain the results of our study in terms of
up-regulation of m-opioid receptors. In contrast, the de-
creased intrinsic activity of methadone after chronic treat-
ment with morphine is consistent with expectations for
down-regulation when the receptor reserve is limited. On the
other hand, the decrease in the Emax could be explained by
changes in the number of receptors and also by changes at
the postreceptor level such as transducer molecules (Kramer
et al., 1997). The fact that the C50 values based on unbound
concentrations were not different between the two groups
leads us to assume that alterations related to the sign trans-
duction processes account for most of the changes in Emax.
Paronis and Holtzman (1992) studied the development of
tolerance to the analgesic activity of several opioids including
methadone after continuous infusion of morphine, meperi-
dine or fentanyl in rats. They found that after previous ex-
posure to morphine, the estimates of ED50 of methadone
were not significantly different from those obtained after a
saline infusion. The fact that they compared ED50 instead of
C50, and that they administered methadone at 24 h after
minipump removal instead of 12 h, as in our study, could play
a role in the differences seen between both studies.
To summarize the results of the current study, spontane-
ous withdrawal was associated with increasing levels of a1-
acid glycoprotein levels in plasma and a decrease in fu in
plasma. The altered protein binding accounted for most of the
changes found in the plasma and brain disposition of meth-
adone. Pharmacodynamic changes reflected by a decrease in
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the maximum attainable analgesic effect were seen after
withdrawal; this result together with the absence of alter-
ations in C50 supports the hypothesis of a change at the
postreceptor level. On the basis of the results reported in the
current study the altered effect versus time profiles found
during withdrawal are mediated mostly by pharmacody-
namic changes.
References
Adams JU and Holtzman SG (1990) Tolerance and dependence after continuous
morphine infusion from osmotic pumps measured by operant responding in rats.
Psychopharmacology 100:451–458.
Beal SL and Sheiner LB (1992) NONMEM Users Guides. NONMEM Project Group.
University of California, San Francisco, CA.
Bhargava H and Gulati A (1990) Down-regulation of brain and spinal cord m-opiate
receptors in morphine tolerant-dependents rats. Eur J Pharmacol 190:21–26.
Bhargava HN, Villar VM, Rahmani NH and Larsen AK (1992) Studies on the
possible role of pharmacokinetics in the development of tolerance to morphine in
rat. Gen Pharmacol 23:1199–1204.
Bla¨sig J, Herz A, Reinhold K, Zieglgansberger S (1973) Development of physical
dependence on morphine in respect to time and dosage and quantification of the
precipited withdrawal syndrome in rats. Physhopharmacology 33:19–38.
Boeckmann AJ, Sheiner LB and Beal SL (1992) NONMEM Users Guides-Part V.
NONMEM Project Group. University of California, San Francisco, CA.
Brase DA (1986) Unequal opiate cross-tolerance to morphine in the locomotor-
activation model in the mouse. Neuropharmacology 25:297–304.
Chen HSG and Gross JF (1979) Estimation of tissue-to-plasma partition coefficients
used in physiological pharmacokinetic models. J Pharmacokin Biopharm 7:117–
125.
Craft RM and Dykstra LA (1990) Differential cross-tolerance to opioids in squirrel
monkeys responding under a shock titration schedule. J Pharmacol Exp Ther
252:945–952.
D’Amour FE and Smith DL (1941) A method for determining loss of pain sensation.
J Pharmacol Exp Ther 72:74–79.
Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS and
Hamon M (1996) International union of pharmacology. XII. Classification of opioid
receptors. Pharmacol Rev 48:567–592.
Dı´az A, Ruiz F, Flo´rez J, Hurle´ MA and Pazos A (1995) m-opioid receptor regulation
during opioid tolerance and supersensitivity in rat central nervous system. J Phar-
macol Exp Ther 274:1545–1551.
Ekblom M, Hammarlund-Udenaes M and Paalzow L (1993) Tolerance development
and rebound effects of morphine in relation to different administrations in rats.
J Pharmacol Exp Ther 266:244–252.
Gårdmark M, Ekblom M, Bouw R and Hammarlund-Udenaes M (1993) Quantifica-
tion of effect delay and acute tolerance development to morphine in the rat.
J Pharmacol Exp Ther 267:1061–1067.
Garrido M. J, Jime´nez R, Go´mez E and Calvo R (1996) Influence of plasma protein
binding on analgesic effect on methadone in rats with spontaneous withdrawal.
J Pharm Pharmacol 48:281–284.
Go´mez E, Martı´nez-Jorda´ R, Sua´rez E, Garrido MJ and Calvo R (1995) Altered
methadone analgesia due to changes in plasma protein binding: Role of the route
of administration. Gen Pharmacol 26:1273–1276.
Goode PG (1971) An implanted reservoir of morphine solution for rapid induction of
physical dependence in rats. Br J Pharmacol 41:558–566.
Grabrielsson JL, Johansson P, Bondesson U and Paalzow LK (1985) Analysis of
methadone disposition in the pregnant rat by means of a physiological flow model.
J Pharmacokinet Biopharm 13:355–372.
Inturrisi CE, Colburn WA, Kaiko RF, Houde RW and Foley KM (1987) Pharmaco-
kinetic and pharmacodynamics of methadone in patients with chronic pain. Clin
Pharmacol Ther 41:392–401.
Kissin I, Brown P T, Robinson A and Bradley E L (1991) Acute tolerance in morphine
analgesia: Continuous infusion and single injection in rats. Anesthesiology 74:
166–171.
Kramer TH, Bartosz-Bechowski H, Davis P, Hruby VJ and Porreca F (1997) Extraor-
dinary potency of a novel delta opioid receptor agonist is due in part to increased
efficacy. Life Sci 61:129–135.
Kristiensen K, Blemmer T, Angelo HR, Christrup LL, Drenk NE, Rasmussen SN and
Sjogren P (1996) Stereoselective pharmacokinetics of methadone in chronic pain
patients. Ther Drug Monitor 18:221–227.
Ling GSF, Umans JG and Inturrisi CE (1981) Methadone: Radioimmunoassay and
pharmacokinetics in the rat. J Pharmacol Exp Ther 217:147–151.
Liu SJ, Roerig DL and Wang RIH (1983) Brain and plasma levels of methadone and
their relationship to analgesic activity of methadone in rats. Drug Metab Dispos
11:335–338.
Magnan J, Paterson SJ, Tavani A and Kosterlitz HW (1982) The binding spectrum
of narcotic analgesic drugs with different agonist and antagonist properties. Nau-
nyn Schmiedebergs Arch Pharmacol 319:197–205.
Mandema JM and Wada DR (1995) Pharmacodynamic model for acute tolerance
development to the electroencephalographic effects of alfentanil in the rat. J Phar-
macol Exp Ther 275:1185–1194.
Marathe PH, Shen DD, Artru AA and Bowdle A (1991) Effect of serum protein
binding on the entry of lidocaine into brain and cerebrospinal fluid in dogs.
Anesthesiology 75:804–812.
March C and Blanke RV (1985) Determination of free valproic acid concentrations
using the Amicon Micropartition MPS-1 ultrafiltration system. Ther Drug Monitor
7:115–120.
Ohtani M, Kotaki H, Sawada Y and Iga T (1994) Comparative analysis of buprenor-
phine and norbuprenorphine induced analgesic effects based on pharmacokinetic-
pharmacodynamic modelling. J Pharmacol Exp Ther 272:505–510.
Oullet DM-C and Pollack GM (1995) A pharmacokinetic-pharmacodynamic model of
tolerance to morphine analgesia during infusion in rats. J Pharmacokin Biopharm
23:531–549.
Ouellet DM-C and Pollack GM (1997). Pharmacodynamics and tolerance develop-
ment during multiple intravenous bolus morphine administration in rats. J Phar-
macol Exp Ther 287:713–720.
Paronis CA and Holtzman SG (1992) Development of tolerance to the analgesic
activity of m-agonists after continuous infusion of morphine, meperidine or fenta-
nyl in rats. J Pharmacol Exp Ther 262:1–9.
Pierce TL, Hope W and Raper C (1996) The induction and quantitation of methadone
dependence in the rat. J Pharmacol Toxicol Meth 36:137–146.
Quin M, Nilsson M and Oie S (1994) Decreased elimination of drug in the presence
of a1-acid glycoprotein is related to a reduced hepatocyte uptake. J Pharmacol Exp
Ther 269:1176–1181.
Rowland M and Tozer TN (1995a) Physiologic concepts and kinetics: Distribution, in
Clinical Pharmacokinetics. Concepts and applications, 3rd ed. (Rowland M and
Tozer TN eds) pp 137–155, William & Wilkins, Media, PA.
Rowland M and Tozer TN (1995b) Physiologic concepts and kinetics: Distribution, in
Clinical Pharmacokinetics. Concepts and applications, 3rd ed. (Rowland M and
Tozer TN eds) pp 156–183, William & Wilkins, Media, PA.
Sheiner LB, Stanski DR, Vozeh S, Miller RD and Ham J (1979) Simultaneous
modeling of pharmacokinetics and pharmacodynamics: Application to d-
tubocuranine. Clin Pharmacol Ther 25:358–371.
Thaw PA and Albutt EC (1980) A critical evaluation of a serum seromucoid assay
and its replacement by a serum a1-glycoprotein assay. Ann Clin Biochem 17:140–
143.
Ullibarri I, Garcı´a-Sevilla JA and Ugedo L (1987) Modulation of brain a2-
adrenoceptor and m-opioid receptor densities during morphine dependence and
spontaneous withdrawal in rats. Naunyn Schmiedebergs Arch Pharmacol 336:
530–537.
Verotta D and Sheiner LB (1987) Simultaneous modeling of pharmacokinetics and
pharmacodynamics: An improved algorithm. Comput Appl Biosc (CABIOS) 3:345–
349.
Vozeh S, Schmidlin O and Taeschner W (1989) Pharmacokinetic drug data, in Drug
data handbook (Clinical Pharmacokinetics ed) pp 1–38, ADIS Press Limited,
Auckland.
Wolff K, Sanderson M, Hay AWM and Raistrick D (1991) Methadone concentrations
in plasma and their relationship to drug dosage. Clin Chem 37:205–209.
Send reprint requests to: Marı´a J. Garrido, Departamento de Farmacologı´a,
Facultad de Medicina, Universidad del Paı´s Vasco, Lejona 48940, Vizcaya,
Spain. E-mail: kfbgacim@lg.ehu.es.
1999 Disposition and Effect of Methadone 187
